Therapeutic Effects of Monoclonal Antibody−β-Lactamase Conjugates in Combination with a Nitrogen Mustard Anticancer Prodrug in Models of Human Renal Cell Carcinoma †

Therapeutic effects of monoclonal antibo

Therapeutic effects of monoclonal antibody g250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts

✍ J. van Dijk; H. Uemura; A. J. M. C. Beniers; W. P. Peelen; S. Th. Zegveld; G. J. 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 1015 KB

Because renal-cell carcinoma (RCC) is considered relatively resistant to radio-and chemotherapy, RCC patients may benefit from new treatment modalities, e.g. immunotherapy. In vitro and in vivo studies suggest that combinations of cytokines such as interferon y or interferon a (IFN-y, IFN-a) and tum